PBC

GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, April 4, 2024
MAA, ACLF, Primary biliary cholangitis, Patient, Research, Ipsen, Placebo, EMA, Bank statement, Marketing, PBC, FDA, EF, Pharmaceutical industry

“A remarkable milestone was reached by GENFIT in 2023 with the announcement of positive topline data for our Phase 3 ELATIVE® trial evaluating elafibranor in Primary Biliary Cholangitis.

Key Points: 
  • “A remarkable milestone was reached by GENFIT in 2023 with the announcement of positive topline data for our Phase 3 ELATIVE® trial evaluating elafibranor in Primary Biliary Cholangitis.
  • This was followed by another asset acquisition in July 2023, where GENFIT licensed the exclusive worldwide rights of CLM-022, a potential first-in-class inflammasome inhibitor, from Celloram.
  • IND was in effect as of April 17, 2023 and the first patient was randomized in the UNVEIL-IT® Phase 2 trial in July 2023.
  • GENFIT equally obtained a “Prime status” label by ISS ESG, upgrading its corporate rating from C to C+.

United Therapeutics Announces the First Comprehensive Review Publication on Xenotransplantation

Retrieved on: 
Tuesday, March 26, 2024
Research, Clinical Trials, Cardiology, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, FRS, Gene editing, Acute liver failure, New product development, UTHR, Patient, United Therapeutics, Lung, Xenotransplantation, Manuscript, MBBS, Regenerative medicine, PBC, Clinical trial, Therapy, Heart, Creativity, Physiology, Kidney, FACS, FRCS, Liver, Physiological Reviews, Food, Pharmaceutical industry

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the online availability of a review manuscript titled “Physiological Basis for Xenotransplantation from Genetically-Modified Pigs to Humans: A Review,” in the journal Physiological Reviews.

Key Points: 
  • United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the online availability of a review manuscript titled “Physiological Basis for Xenotransplantation from Genetically-Modified Pigs to Humans: A Review,” in the journal Physiological Reviews.
  • Beyond xenotransplantation, United Therapeutics has six other organ manufacturing programs in the lung, kidney, and liver using three distinct platforms: regenerative medicine, bio-artificial organs, and 3-D organ printing.
  • United Therapeutics believes that this study will be the first human clinical trial of a manufactured organ.
  • At United Therapeutics, our vision and mission are one.

United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program

Retrieved on: 
Monday, March 25, 2024
Biotechnology, Pharmaceutical, Health, Cardiology, UTHR, Patient, ASR, PBC, Sale, Therapy, Creativity, Citibank, Pharmaceutical industry

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that its Board of Directors has authorized the company to purchase up to $1 billion of United Therapeutics’ common stock.

Key Points: 
  • United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that its Board of Directors has authorized the company to purchase up to $1 billion of United Therapeutics’ common stock.
  • This program builds on United Therapeutics’ planned $400 million paydown of its revolving credit facility in 2024, of which $100 million was paid down during the first quarter of 2024.
  • To enact the program, United Therapeutics today will enter into an Accelerated Share Repurchase (ASR) agreement with Citibank, N.A.
  • At final settlement of the ASR agreement, United Therapeutics may be entitled to receive additional shares of United Therapeutics’ common stock, or, under certain limited circumstances, be required to make cash payment to Citi or, if United Therapeutics elects, deliver shares to Citi.

Gilead Sciences Announces Completion of Acquisition of CymaBay

Retrieved on: 
Friday, March 22, 2024
Health, Hospitals, General Health, Research, Science, Pharmaceutical, Biotechnology, EPS, Patient, Gilead Sciences, Acquisition, Primary biliary cholangitis, PBC, Therapy, Safety, Itch, Pharmaceutical industry

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for approximately $4.3 billion in total equity value.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for approximately $4.3 billion in total equity value.
  • “The acquisition of CymaBay brings us a potential best in disease therapy that could transform the treatment landscape for people with primary biliary cholangitis,” said Daniel O’Day, Chairman and Chief Executive Officer, Gilead Sciences.
  • “I want to thank the CymaBay team for their efforts and commitment to addressing this high unmet need.
  • Pursuant to the merger agreement, Gilead and Purchaser commenced a tender offer on February 23, 2024, to acquire all outstanding shares of CymaBay at a price of $32.50 per share.

SOURCE Global, Microsoft Collaborate to Help Provide Clean Drinking Water in Navajo Nation

Retrieved on: 
Friday, March 22, 2024
Environment, Construction & Property, Environmental Health, Building Systems, Alternative Energy, Green Technology, Energy, Other Natural Resources, Natural Resources, Microsoft, Health, Sanitation, Taste, Atmospheric water generator, United, Sustainable Development Goals, Climate, United Nations, Navajo Nation, PBC, Investment, Atmosphere, Water, Drinking water, Renewable energy

SOURCE Global, PBC and Microsoft today announced an initiative to provide 100 Navajo Nation families with SOURCE Hydropanel drinking water systems.

Key Points: 
  • SOURCE Global, PBC and Microsoft today announced an initiative to provide 100 Navajo Nation families with SOURCE Hydropanel drinking water systems.
  • An estimated 30 percent of Navajo Nation residents — about 70,000 people — don’t have access to clean, safe drinking water.
  • Access to clean drinking water is not just an issue reserved for developing nations, more than 2M Americans lack access to clean water in their home.
  • “Microsoft’s Climate innovation Fund was launched in 2020 to address climate-related challenges like water access,” said Eliza Roberts, Water Lead at Microsoft.

Price.com Announces Collaboration with Mark Cuban Cost Plus Drug Company to Make Prescription Drugs More Affordable

Retrieved on: 
Tuesday, April 2, 2024
Cost Plus Drugs, Partnership, Health, PBC, Pharmaceutical industry

LOS ANGELES, April 2, 2024 /PRNewswire/ -- In a significant step to improve healthcare affordability, Price.com has joined forces with Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs), marking a notable phase of transparency and ease of access in the prescription drug market.

Key Points: 
  • LOS ANGELES, April 2, 2024 /PRNewswire/ -- In a significant step to improve healthcare affordability, Price.com has joined forces with Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs), marking a notable phase of transparency and ease of access in the prescription drug market.
  • This joint effort aims to help consumers by providing a straightforward platform for comparing drug prices, making prescription medications more affordable.
  • "We are thrilled to collaborate with Price.com in our mission to make prescription drugs more affordable for consumers," said Alex Oshmyansky, CEO of Mark Cuban Cost Plus Drug Company.
  • "At Cost Plus Drugs, our commitment to transparent drug pricing has always been unwavering, and with Price.com, we are dedicated to providing affordable and accessible healthcare solutions for all."

Agcor and AgWare Celebrate 2 Years of Groundbreaking Integration, Setting the Standard in Agricultural Appraisal Efficiency

Retrieved on: 
Thursday, March 21, 2024
Peafowl, Partnership, Organization, PBC, Heart

For over two years, the integration between Agcor and AgWare has been redefining the efficiency and accuracy of agricultural lending appraisals.

Key Points: 
  • For over two years, the integration between Agcor and AgWare has been redefining the efficiency and accuracy of agricultural lending appraisals.
  • The partnership originated from shared recognition of challenges faced by agricultural lenders, particularly in transferring the extensive data from Agcor's platform to AgWare's appraisal software.
  • Through this integration, appraisers are empowered to automatically populate Agcor data into AgWare, eliminating the need for manual data entry.
  • "Our teams are actively working on future enhancements that will further streamline the appraisal process and empower agricultural lenders with unparalleled efficiency and accuracy."

Accushield and Serviam Collaborate to Combat Resident Loneliness in Senior Living

Retrieved on: 
Wednesday, March 20, 2024
Depression, Health, Prevalence, Caregiver, Network, Partnership, Pharmacy, Value, Social isolation, Standard of care, Attention, Volunteering, Quality of life, PBC, Ecosystem, Nursing, CSO, Loneliness, Management

Accushield and Serviam are committed to revolutionizing the landscape of senior care in America, placing resident well-being at the forefront, and fostering a sustainable financial future for senior living operators.

Key Points: 
  • Accushield and Serviam are committed to revolutionizing the landscape of senior care in America, placing resident well-being at the forefront, and fostering a sustainable financial future for senior living operators.
  • Serviam equips senior living operators to thrive within a value-based care framework by establishing a powerful ecosystem of technology and consultative services.
  • Accushield will partner with senior living communities and other engagement platforms to support seniors identified with low scores on the UCLA-3 Loneliness Scale.
  • "Through our partnership with Serviam, we are dedicated to combating loneliness in senior living communities," stated Charles Mann, Founder and CSO of Accushield.

Burkland Launches Dedicated Services for Clean Energy Startups

Retrieved on: 
Wednesday, March 13, 2024
CHIPS, Consumer, HR, Software as a service, CFO, National Science Foundation, Name, SAN, Accounting, Blog, Perovskite, Aviation, Science, Food, Carbon, PBC, Tandem, Primary energy, Soil, Inflation, Government

SAN FRANCISCO, March 13, 2024 /PRNewswire-PRWeb/ -- Burkland, a full-service fractional CFO, HR, accounting, and tax provider, today announces a new dedicated specialty practice team designed to meet the needs of startups in clean energy. Accounting and financial experts are helping these newly founded companies grow, with strategies tailored to their unique needs and requirements, such as guidance on how to navigate fundraising complexities and manage government grants.

Key Points: 
  • SAN FRANCISCO, March 13, 2024 /PRNewswire-PRWeb/ -- Burkland , a full-service fractional CFO, HR, accounting, and tax provider, today announces a new dedicated specialty practice team designed to meet the needs of startups in clean energy.
  • "Many Burkland clients are hard at work innovating in clean energy, and several have already been recipients of government funds," said Emily Felicelli, Burkland Clean Energy/Grant Accounting Division Lead.
  • "Many Burkland clients are hard at work innovating in clean energy, and several have already been recipients of government funds," said Emily Felicelli , Burkland Clean Energy/Grant Accounting Division Lead.
  • Additional clean energy focus areas for Burkland clients include:
    Burkland experts work with startups across a spectrum of industries, including SaaS, Healthcare, Consumer, Clean Energy, and Fintech, focusing on helping founders succeed.

Response to National Joint Board of Investigation into the release and supervision of Myles Sanderson

Retrieved on: 
Tuesday, March 12, 2024
Organization, CSC, BOI, Corrections, UAL, Homicide, Risk, Domestic violence, Mental health, Policy, Hope, James Smith Cree Nation, Parole board, PBC, Cree, Work, Police

The Correctional Service of Canada (CSC) and the Parole Board of Canada (PBC) responded today to the results and recommendations of a National Joint Board of Investigation (BOI) into the case of Myles Sanderson, who was a first-time federal offender on statutory release.

Key Points: 
  • The Correctional Service of Canada (CSC) and the Parole Board of Canada (PBC) responded today to the results and recommendations of a National Joint Board of Investigation (BOI) into the case of Myles Sanderson, who was a first-time federal offender on statutory release.
  • This included the case preparation leading to the statutory release and community supervision as well as the PBC decisions related to Myles Sanderson.
  • This National Joint BOI process was guided by requirements set out in the Corrections and Conditional Release Act.
  • The offender, Myles Sanderson, was released in the community on statutory release in August 2021 under CSC's supervision.